Beta Drugs Intrinsic Value
BETA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹394.00 | ₹354.60 - ₹433.40 | -75.9% | Book Value/Share: ₹197.00, P/B: 2.0x |
| Simple DCF (5Y) | dcf | ₹654.36 | ₹523.49 - ₹785.23 | -60.0% | CF Growth: 15.0%, Discount: 15% |
Want to compare with current market value? Check BETA share price latest .
Valuation Comparison Chart
BETA Intrinsic Value Analysis
What is the intrinsic value of BETA?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Beta Drugs (BETA) is ₹654.36 (median value). With the current market price of ₹1635.90, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹394.00 to ₹654.36, indicating ₹394.00 - ₹654.36.
Is BETA undervalued or overvalued?
Based on our multi-method analysis, Beta Drugs (BETA) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.43 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.21 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
Related Pages for Beta Drugs
Additional stock information and data for BETA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹36 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹31 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹23 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹30 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹19 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |